Ozer A B, Bolat E, Erhan O L, Kilinc M, Demirel I, Toprak G Caglar
Department of Anesthesiology and Reanimation, Firat University Medical School, Elazig, Turkey.
Anesthesiology and Reanimation Clinics, Elazig Training and Research Hospital, Elazig, Turkey.
Niger J Clin Pract. 2018 Feb;21(2):139-142. doi: 10.4103/njcp.njcp_322_16.
Sugammadex has steroid-encapsulating effect.
This study was undertaken to assess whether the clinical efficacy of sugammadex was altered by the administration of steroids.
Sixty patients between 18 and 60 years of age with the American Society of Anesthesiologists I-IV and undergoing elective direct laryngoscopy/biopsy were included in this study.
Patients were assigned to two groups based on the intraoperative steroid use: those who received steroid (Group S) and who did not (Group C). After standard general anesthesia, patients were monitored with the train of four (TOF) monitoring. The preferred steroid and its dose, timing of steroid administration, and TOF value before and after sugammadex as well as the time to recovery (TOF of 0.9) were recorded.
SPSS software version 17.0 was used for statistical analysis.
There is no statistically significant difference between groups in terms of age, gender, preoperative medication use, and TOF ratio just before administering sugammadex. The reached time to TOF 0.9 after sugammadex administration was significantly shorter in Group S than Group C (P < 0.05). A within-group comparison in Group S showed no difference in TOF ratio immediately before sugammadex as well as the dose of sugammadex in those who received prednisolone; time to TOF 0.9 was higher in prednisolone receivers as compared to dexamethasone receivers (P < 0.05).
In patients receiving steroids, and particularly dexamethasone, an earlier reversal of neuromuscular block by sugammadex was found, in contrast with what one expect. Further studies are required to determine the cause of this effect which is probably due to a potential interaction between sugammadex and steroids.
舒更葡糖钠具有包裹类固醇的作用。
本研究旨在评估类固醇的使用是否会改变舒更葡糖钠的临床疗效。
本研究纳入了60例年龄在18至60岁之间、美国麻醉医师协会分级为I-IV级且接受择期直接喉镜检查/活检的患者。
根据术中是否使用类固醇将患者分为两组:接受类固醇治疗的患者(S组)和未接受类固醇治疗的患者(C组)。在标准全身麻醉后,使用四个成串刺激(TOF)监测对患者进行监测。记录使用的首选类固醇及其剂量、类固醇给药时间、舒更葡糖钠给药前后的TOF值以及恢复时间(TOF为0.9)。
采用SPSS 17.0软件进行统计分析。
两组在年龄、性别、术前用药情况以及给予舒更葡糖钠之前的TOF比值方面无统计学显著差异。S组给予舒更葡糖钠后达到TOF 0.9的时间明显短于C组(P < 0.05)。S组内比较显示,接受泼尼松龙的患者在给予舒更葡糖钠之前的TOF比值以及舒更葡糖钠剂量无差异;与接受地塞米松的患者相比,接受泼尼松龙的患者达到TOF 0.9的时间更长(P < 0.05)。
在接受类固醇治疗的患者中,尤其是接受地塞米松治疗的患者,发现舒更葡糖钠能更早地逆转神经肌肉阻滞,这与预期相反。需要进一步研究以确定这种效应的原因,这可能是由于舒更葡糖钠与类固醇之间存在潜在相互作用。